Our top pick for
Zosano Pharma Corp is a biotechnology business based in the US. Zosano Pharma shares (ZSAN) are listed on the NASDAQ and all prices are listed in US Dollars. Zosano Pharma employs 40 staff and has a trailing 12-month revenue of around $659,000.
|Latest market close||$0.30|
|52-week range||$0.75 - $29.75|
|50-day moving average||$1.38|
|200-day moving average||$0.92|
|Wall St. target price||$21.00|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-15.69|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2022-09-17)||N/A|
|1 month (2022-08-24)||N/A|
|3 months (2022-06-28)||3.45%|
|6 months (2022-03-28)||41.51%|
|1 year (2021-09-28)||-59.46%|
|2 years (2020-09-28)||-81.93%|
|3 years (2019-09-27)||1.61|
|5 years (2017-09-28)||0.83|
|Gross profit TTM||$-20,985,000|
|Return on assets TTM||-41.86%|
|Return on equity TTM||-192.97%|
|Market capitalisation||$2.7 million|
TTM: trailing 12 months
We're not expecting Zosano Pharma to pay a dividend over the next 12 months.
Zosano Pharma's shares were split on a 1:35 basis on 12 April 2022. So if you had owned 35 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Zosano Pharma shares – just the quantity. However, indirectly, the new 3400% higher share price could have impacted the market appetite for Zosano Pharma shares which in turn could have impacted Zosano Pharma's share price.
Over the last 12 months, Zosano Pharma's shares have ranged in value from as little as $0.75 up to $29.75. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Zosano Pharma's is 3.2854. This would suggest that Zosano Pharma's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics and other bioactive molecules to patients suffering from migraine using its transdermal microneedle system. Its lead product candidate is Qtrypta (M207), a proprietary formulation of zolmitriptan used for the acute treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California. On June 1, 2022, Zosano Pharma Corporation filed a voluntary petition for reorganization under Chapter 11 in the U. S. Bankruptcy Court for the District of Delaware. .
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.